SI2794667T1 - Low anticoagulant heparins - Google Patents

Low anticoagulant heparins Download PDF

Info

Publication number
SI2794667T1
SI2794667T1 SI201231283T SI201231283T SI2794667T1 SI 2794667 T1 SI2794667 T1 SI 2794667T1 SI 201231283 T SI201231283 T SI 201231283T SI 201231283 T SI201231283 T SI 201231283T SI 2794667 T1 SI2794667 T1 SI 2794667T1
Authority
SI
Slovenia
Prior art keywords
chemically modified
kda
heparin
modified heparin
molecular weight
Prior art date
Application number
SI201231283T
Other languages
English (en)
Slovenian (sl)
Inventor
Hans-Peter Ekre
Ulf Lindahl
Erik Holmer
Per-Olov Eriksson
Anna Leitgeb
Mats Wahlgren
Stefania Tidia
Lino Liverani
Original Assignee
Modus Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modus Therapeutics Ab filed Critical Modus Therapeutics Ab
Publication of SI2794667T1 publication Critical patent/SI2794667T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078Degradation products
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201231283T 2011-12-19 2012-12-19 Low anticoagulant heparins SI2794667T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/SE2011/051538 WO2013095215A1 (en) 2011-12-19 2011-12-19 Low anticoagulant heparins
PCT/SE2012/051428 WO2013095276A1 (en) 2011-12-19 2012-12-19 Low anticoagulant heparins
EP12860938.5A EP2794667B1 (en) 2011-12-19 2012-12-19 Low anticoagulant heparins

Publications (1)

Publication Number Publication Date
SI2794667T1 true SI2794667T1 (en) 2018-06-29

Family

ID=48668926

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201231283T SI2794667T1 (en) 2011-12-19 2012-12-19 Low anticoagulant heparins
SI201231282T SI2794666T1 (en) 2011-12-19 2012-12-19 Use of chemically modified heparin derivatives in sickle cell disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201231282T SI2794666T1 (en) 2011-12-19 2012-12-19 Use of chemically modified heparin derivatives in sickle cell disease

Country Status (26)

Country Link
US (2) US9480702B2 (cg-RX-API-DMAC7.html)
EP (2) EP2794666B1 (cg-RX-API-DMAC7.html)
JP (2) JP6703806B2 (cg-RX-API-DMAC7.html)
CN (1) CN104053675B (cg-RX-API-DMAC7.html)
AU (1) AU2012354226B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014014673B1 (cg-RX-API-DMAC7.html)
CA (2) CA2856918C (cg-RX-API-DMAC7.html)
CY (2) CY1120197T1 (cg-RX-API-DMAC7.html)
DK (2) DK2794667T3 (cg-RX-API-DMAC7.html)
ES (2) ES2668273T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20180726T1 (cg-RX-API-DMAC7.html)
HU (2) HUE037555T2 (cg-RX-API-DMAC7.html)
IL (1) IL232903A (cg-RX-API-DMAC7.html)
IN (1) IN2014MN01056A (cg-RX-API-DMAC7.html)
MX (1) MX358439B (cg-RX-API-DMAC7.html)
MY (1) MY170069A (cg-RX-API-DMAC7.html)
NO (2) NO2794666T3 (cg-RX-API-DMAC7.html)
PH (1) PH12014501387B1 (cg-RX-API-DMAC7.html)
PL (2) PL2794666T3 (cg-RX-API-DMAC7.html)
PT (2) PT2794666T (cg-RX-API-DMAC7.html)
RS (2) RS57214B1 (cg-RX-API-DMAC7.html)
SI (2) SI2794667T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201800217T1 (cg-RX-API-DMAC7.html)
TN (2) TN2014000236A1 (cg-RX-API-DMAC7.html)
WO (3) WO2013095215A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403654B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095279A1 (en) 2011-12-19 2013-06-27 Dilafor Ab Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
EP3137099B1 (en) * 2014-04-30 2019-09-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Dnase for use in treating vaso-occlusive crisis
EP2965764A1 (en) * 2014-07-11 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
US12220500B2 (en) * 2018-04-13 2025-02-11 University Of Virginia Patent Foundation Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels
CN109481692A (zh) * 2018-11-30 2019-03-19 东南大学 一种青蒿琥酯肝素衍生物及其药物组合物和应用
WO2023192344A1 (en) * 2022-03-29 2023-10-05 The Penn State Research Foundation Device and method for accelerating and guiding vascularization
US12444880B2 (en) 2022-05-05 2025-10-14 Tego Innovations, Inc. Magnetic power distribution assembly
US20250353936A1 (en) * 2022-06-06 2025-11-20 Ihp Therapeutics Inc. Chemically modified heparin
CN115448994B (zh) * 2022-09-28 2023-08-01 山东大学 一种可中和抗凝低分子量肝素及其制备方法和应用
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
GB2625581A (en) * 2022-12-21 2024-06-26 Modus Therapeutics Ab New medical use
GB2627263A (en) * 2023-02-17 2024-08-21 Modus Therapeutics Ab New medical use
WO2024170746A1 (en) 2023-02-17 2024-08-22 Modus Therapeutics Ab New medical use of sevuparin in the treatment of endotoxemia
CN116854838A (zh) * 2023-06-30 2023-10-10 重庆望业药物研究有限公司 低分子多糖及其制备方法与应用
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
DE68906345T2 (de) * 1988-10-07 1993-10-28 Hoechst Ag Antimalariazusammenstellungen, gebrauchmachend von Quinidin, Artemisinin und ihren Derivaten.
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) * 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
ATE224918T1 (de) * 1995-03-31 2002-10-15 Hamilton Civic Hospitals Res Zusammensetzung zur hemmung der thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
EP1033375A4 (en) * 1997-11-20 2002-04-24 Ikuo Yamashina MODIFICATION OF LOW MOLECULAR MASS HEPARIN AND REMEDY FOR SKIN Ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
EP1059304B1 (en) 1998-02-26 2006-04-26 Seikagaku Corporation Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
EP1022289B1 (en) * 1998-07-31 2004-07-07 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
CZ20014665A3 (cs) * 1999-06-30 2002-05-15 Hamilton Civic Hospitals Research Development, Inc Prostředek s obsahem heparinu se střední molekulovou hmotností
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
DK1319183T3 (da) * 2000-09-12 2009-05-18 Massachusetts Inst Technology Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2003088980A1 (en) * 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
EP2258349B1 (en) * 2004-05-11 2014-07-16 Egalet Ltd. Swellable dosage form comprising gellan gum
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
EP1906975A4 (en) * 2005-07-22 2010-10-06 Trf Pharma Inc METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE
EP1906974A4 (en) * 2005-07-22 2010-06-23 Univ California HEPARINE COMPOSITIONS AND SELECTIN INHIBITION
EP2447285A3 (en) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
WO2009059284A2 (en) * 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
JP5758797B2 (ja) * 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
CA2767560A1 (en) * 2008-07-25 2010-01-28 Alphapharm Pty Ltd Atovaquone with a particle size diameter range (d90) of greater than 3um to about 10um
CA2758520A1 (en) 2009-04-16 2010-10-21 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
WO2011000032A1 (en) * 2009-06-30 2011-01-06 Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
WO2013095279A1 (en) 2011-12-19 2013-06-27 Dilafor Ab Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
CA2868479A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest
CA2868444A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor

Also Published As

Publication number Publication date
DK2794666T3 (en) 2018-04-23
JP6703806B2 (ja) 2020-06-03
JP2018154848A (ja) 2018-10-04
TN2014000237A1 (en) 2015-09-30
CA2856918A1 (en) 2013-06-27
CY1120197T1 (el) 2018-12-12
CA2856918C (en) 2017-07-04
PH12014501387A1 (en) 2014-09-22
BR112014014673A8 (pt) 2017-07-04
CY1120194T1 (el) 2018-12-12
NZ625096A (en) 2016-07-29
CA2856477A1 (en) 2013-06-27
HUE037555T2 (hu) 2018-09-28
PT2794666T (pt) 2018-05-09
NO2794667T3 (cg-RX-API-DMAC7.html) 2018-07-21
BR112014014673A2 (pt) 2017-06-13
JP2015500387A (ja) 2015-01-05
IL232903A (en) 2017-02-28
MX2014006956A (es) 2014-10-17
DK2794667T3 (en) 2018-04-23
HK1200471A1 (en) 2015-08-07
EP2794667B1 (en) 2018-02-21
US9480701B2 (en) 2016-11-01
HUE037554T2 (hu) 2018-09-28
EP2794667A1 (en) 2014-10-29
SI2794666T1 (en) 2018-06-29
WO2013095215A1 (en) 2013-06-27
HK1199893A1 (en) 2015-07-24
CN104053675B (zh) 2016-10-12
MX358439B (es) 2018-08-21
AU2012354226B2 (en) 2017-01-12
US20150031638A1 (en) 2015-01-29
HRP20180726T1 (hr) 2018-06-15
RS57214B1 (sr) 2018-07-31
EP2794666B1 (en) 2018-02-21
IL232903A0 (en) 2014-07-31
RS57213B1 (sr) 2018-07-31
NO2794666T3 (cg-RX-API-DMAC7.html) 2018-07-21
PL2794667T3 (pl) 2018-09-28
ZA201403654B (en) 2017-08-30
ES2668273T3 (es) 2018-05-17
TN2014000236A1 (en) 2015-09-30
US9480702B2 (en) 2016-11-01
CA2856477C (en) 2017-06-27
WO2013095276A1 (en) 2013-06-27
ES2669055T3 (es) 2018-05-23
SMT201800218T1 (it) 2018-05-02
AU2012354226A1 (en) 2014-06-05
BR112014014673B1 (pt) 2021-02-17
HRP20180725T1 (hr) 2018-06-29
PT2794667T (pt) 2018-05-16
EP2794667A4 (en) 2015-07-22
PL2794666T3 (pl) 2018-08-31
EP2794666A1 (en) 2014-10-29
MY170069A (en) 2019-07-03
IN2014MN01056A (cg-RX-API-DMAC7.html) 2015-05-01
US20140364369A1 (en) 2014-12-11
EP2794666A4 (en) 2015-07-22
WO2013095277A1 (en) 2013-06-27
PH12014501387B1 (en) 2014-09-22
SMT201800217T1 (it) 2018-05-02
CN104053675A (zh) 2014-09-17

Similar Documents

Publication Publication Date Title
SI2794667T1 (en) Low anticoagulant heparins
Volpi Therapeutic applications of glycosaminoglycans
CA2397964A1 (en) Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
JP2015500387A5 (cg-RX-API-DMAC7.html)
CA2457719A1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
RU2010122324A (ru) Полисахаридные композиции, не обладающие антикоагулянтными свойствами
SI2794665T1 (en) Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
CA2874216C (en) Low-molecular-weight biotechnological chondroitin 6-sulphate for prevention of osteoarthritis
US20110152509A1 (en) Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
KR0148799B1 (ko) 항아테롬성 동맥경화 활성을 갖는 신규한 황산더마탄 및 헤파린 올리고당류
JP2003523460A5 (cg-RX-API-DMAC7.html)
JP2015500388A5 (cg-RX-API-DMAC7.html)
US11248063B2 (en) Derivatives of N-desulfated glycosaminoglycans and use as drugs
CA2489862C (en) Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation
JPH10218902A5 (cg-RX-API-DMAC7.html)
Sun et al. Sulfated polysaccharide heparin used as carrier to load hydrophobic lappaconitine
ES2792298B2 (es) Procedimiento para la obtencion de heparinas de bajo peso molecular y heparinas de bajo peso molecular obtenidas por el mismo
Bisio et al. Carbohydrate‐Based Antithrombotics
US20120253029A1 (en) Process for the preparation of highly o-sulfated epimerized derivatives of k5 polysaccharide and intermediates therein
ZA200410358B (en) Low molecular weight oversulfated polysaccharide.